Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application
出版年份 2011 全文链接
标题
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application
作者
关键词
-
出版物
International Braz J Urol
Volume 36, Issue 3, Pages 273-282
出版商
FapUNIFESP (SciELO)
发表日期
2011-02-25
DOI
10.1590/s1677-55382010000300003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
- (2017) D. J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group
- (2017) R. Dreicer et al. JOURNAL OF CLINICAL ONCOLOGY
- Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
- (2009) William E. Osai et al. ANTI-CANCER DRUGS
- No Strong Association Between HER-2/neu Protein Overexpression and Gene Amplification in High-grade Invasive Urothelial Carcinomas
- (2009) Vildan Caner et al. PATHOLOGY & ONCOLOGY RESEARCH
- Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer
- (2009) Tibor Szarvas et al. PATHOLOGY & ONCOLOGY RESEARCH
- HER2Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated WithMYCCoamplification in a Subset of Cases
- (2008) Donna E. Hansel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Molecular Pathogenesis and Diagnostics of Bladder Cancer
- (2008) Anirban P. Mitra et al. Annual Review of Pathology-Mechanisms of Disease
- The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.
- (2008) Anna Bagnato et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells
- (2008) P. C. Black et al. CLINICAL CANCER RESEARCH
- Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
- (2008) Mei Wu et al. CLINICAL THERAPEUTICS
- Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors
- (2008) Margaret A Knowles Future Oncology
- ERRATUM
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?
- (2008) Wassim Kassouf et al. JOURNAL OF UROLOGY
- Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
- (2008) J. L. Martinez-Torrecuadrada et al. MOLECULAR CANCER THERAPEUTICS
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Growth factors and receptors as prognostic markers in urothelial carcinoma
- (2008) Peter C. Black et al. Current Urology Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started